Immune profiles and DNA methylation alterations related with non-muscle-invasive bladder cancer outcomes

BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) patients receive frequent monitoring because ≥ 70% will have recurrent disease. However, screening is invasive, expensive, and associated with significant morbidity making bladder cancer the most expensive cancer to treat per capita. There is an...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ji-Qing, Salas, Lucas A., Wiencke, John K., Koestler, Devin C., Molinaro, Annette M., Andrew, Angeline S., Seigne, John D., Karagas, Margaret R., Kelsey, Karl T., Christensen, Brock C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783448/
https://www.ncbi.nlm.nih.gov/pubmed/35063012
http://dx.doi.org/10.1186/s13148-022-01234-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783448/
https://www.ncbi.nlm.nih.gov/pubmed/35063012
http://dx.doi.org/10.1186/s13148-022-01234-6

Ejemplares similares